 Mesalamine
"Mesalamine" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An anti-inflammatory agent, structurally related to the SALICYLATES, which is active in INFLAMMATORY BOWEL DISEASE. It is considered to be the active moiety of SULPHASALAZINE. (From Martindale, The Extra Pharmacopoeia, 30th ed)
| Descriptor ID |
D019804
|
| MeSH Number(s) |
D02.241.223.100.050.300.500 D02.241.223.100.300.595.100.540 D02.241.511.390.595.100.540 D02.455.426.559.389.127.020.452.750 D02.455.426.559.389.127.281.595.100.540 D02.455.426.559.389.657.410.595.100.540
|
| Concept/Terms |
Mesalamine- Mesalamine
- meta-Aminosalicylic Acid
- meta Aminosalicylic Acid
- Mesalazine
- 5-Aminosalicylic Acid
- 5 Aminosalicylic Acid
- m-Aminosalicylic Acid
- m Aminosalicylic Acid
Fivasa- Fivasa
- Norgine Brand of Mesalamine
Mesasal- Mesasal
- GlaxoSmithKline Brand of Mesalamine
Novo-5 ASA- Novo-5 ASA
- Novo 5 ASA
- Novo5 ASA
- Novopharm Brand of Mesalamine
Pentasa- Pentasa
- Ferring Brand of Mesalamine
- Yamanouchi Brand of Mesalamine
- Allphar Brand of Mesalamine
Rowasa- Rowasa
- Solvay Brand of Mesalamine
Asacol- Asacol
- Procter & Gamble Brand of Mesalamine
- Byk Brand of Mesalamine
Asacolon- Asacolon
- Celltech Brand of Mesalamine
Ascolitin- Ascolitin
- Sanofi Synthelabo Brand of Mesalamine
- Henning Berlin Brand of Mesalamine
Canasa- Canasa
- Axcan Brand of Mesalamine
- Salofalk
- Farmasa Brand of Mesalamine
- Provalis Brand of Mesalamine
- Antigen Brand of Mesalamine
- Falk Brand of Mesalamine
Claversal- Claversal
- SmithKline Brand of Mesalamine
- Merckle Brand of Mesalamine
Lixacol- Lixacol
- Schering-Plough Brand of Mesalamine
- Schering Plough Brand of Mesalamine
|
Below are MeSH descriptors whose meaning is more general than "Mesalamine".
Below are MeSH descriptors whose meaning is more specific than "Mesalamine".
This graph shows the total number of publications written about "Mesalamine" by people in this website by year, and whether "Mesalamine" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1993 | 0 | 1 | 1 | | 2011 | 0 | 1 | 1 | | 2017 | 1 | 0 | 1 | | 2018 | 0 | 1 | 1 | | 2019 | 1 | 1 | 2 |
To return to the timeline, click here.
Below are the most recent publications written about "Mesalamine" by people in Profiles.
-
Hyams JS, Davis Thomas S, Gotman N, Haberman Y, Karns R, Schirmer M, Mo A, Mack DR, Boyle B, Griffiths AM, LeLeiko NS, Sauer CG, Keljo DJ, Markowitz J, Baker SS, Rosh J, Baldassano RN, Patel A, Pfefferkorn M, Otley A, Heyman M, Noe J, Oliva-Hemker M, Rufo PA, Strople J, Ziring D, Guthery SL, Sudel B, Benkov K, Wali P, Moulton D, Evans J, Kappelman MD, Marquis MA, Sylvester FA, Collins MH, Venkateswaran S, Dubinsky M, Tangpricha V, Spada KL, Saul B, Wang J, Serrano J, Hommel K, Marigorta UM, Gibson G, Xavier RJ, Kugathasan S, Walters T, Denson LA. Clinical and biological predictors of response to standardised paediatric colitis therapy (PROTECT): a multicentre inception cohort study. Lancet. 2019 04 27; 393(10182):1708-1720.
-
Haberman Y, Karns R, Dexheimer PJ, Schirmer M, Somekh J, Jurickova I, Braun T, Novak E, Bauman L, Collins MH, Mo A, Rosen MJ, Bonkowski E, Gotman N, Marquis A, Nistel M, Rufo PA, Baker SS, Sauer CG, Markowitz J, Pfefferkorn MD, Rosh JR, Boyle BM, Mack DR, Baldassano RN, Shah S, Leleiko NS, Heyman MB, Grifiths AM, Patel AS, Noe JD, Aronow BJ, Kugathasan S, Walters TD, Gibson G, Thomas SD, Mollen K, Shen-Orr S, Huttenhower C, Xavier RJ, Hyams JS, Denson LA. Ulcerative colitis mucosal transcriptomes reveal mitochondriopathy and personalized mechanisms underlying disease severity and treatment response. Nat Commun. 2019 01 03; 10(1):38.
-
Schirmer M, Denson L, Vlamakis H, Franzosa EA, Thomas S, Gotman NM, Rufo P, Baker SS, Sauer C, Markowitz J, Pfefferkorn M, Oliva-Hemker M, Rosh J, Otley A, Boyle B, Mack D, Baldassano R, Keljo D, LeLeiko N, Heyman M, Griffiths A, Patel AS, Noe J, Kugathasan S, Walters T, Huttenhower C, Hyams J, Xavier RJ. Compositional and Temporal Changes in the Gut Microbiome of Pediatric Ulcerative Colitis Patients Are Linked to Disease Course. . 2018 10 10; 24(4):600-610.e4.
-
Hyams JS, Davis S, Mack DR, Boyle B, Griffiths AM, LeLeiko NS, Sauer CG, Keljo DJ, Markowitz J, Baker SS, Rosh J, Baldassano RN, Patel A, Pfefferkorn M, Otley A, Heyman M, Noe J, Oliva-Hemker M, Rufo P, Strople J, Ziring D, Guthery SL, Sudel B, Benkov K, Wali P, Moulton D, Evans J, Kappelman MD, Marquis A, Sylvester FA, Collins MH, Venkateswaran S, Dubinsky M, Tangpricha V, Spada KL, Britt A, Saul B, Gotman N, Wang J, Serrano J, Kugathasan S, Walters T, Denson LA. Factors associated with early outcomes following standardised therapy in children with ulcerative colitis (PROTECT): a multicentre inception cohort study. Lancet Gastroenterol Hepatol. 2017 12; 2(12):855-868.
-
Turner D, Travis SP, Griffiths AM, Ruemmele FM, Levine A, Benchimol EI, Dubinsky M, Alex G, Baldassano RN, Langer JC, Shamberger R, Hyams JS, Cucchiara S, Bousvaros A, Escher JC, Markowitz J, Wilson DC, van Assche G, Russell RK. Consensus for managing acute severe ulcerative colitis in children: a systematic review and joint statement from ECCO, ESPGHAN, and the Porto IBD Working Group of ESPGHAN. Am J Gastroenterol. 2011 Apr; 106(4):574-88.
-
Griffiths A, Koletzko S, Sylvester F, Marcon M, Sherman P. Slow-release 5-aminosalicylic acid therapy in children with small intestinal Crohn's disease. J Pediatr Gastroenterol Nutr. 1993 Aug; 17(2):186-92.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|